I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Denis Burger Biography and Net Worth

Director of Aptose Biosciences

Dr. Denis R. Burger currently is the executive chairman of BioCurex, Inc., a company based in Richmond, Canada. Previously, he co-founded Trinity Biotech, PLC, a diagnostic biotechnology company based in Dublin, Ireland, where he was Chairman from 1992 to 1995 and now serves on its board of directors. Dr. Burger was the past chairman, chief executive officer, and a director of AVI Biopharma Inc., an Oregon-based biotechnology company. Dr. Burger is also a partner in Sovereign Ventures, a healthcare consulting and funding firm based in Portland, Oregon. He was a co-founder and chairman of Epitope Inc. from 1981 to 1990. In addition, Dr. Burger has held a professorship in the Department of Microbiology and Immunology and Surgery (Surgical Oncology) at the Oregon Health Sciences University in Portland. Dr. Burger received his Master of Science and Doctor of Philosophy in Microbiology and Immunology from the University of Arizona.

How do I contact Denis R. Burger?: The corporate mailing address for Dr. Burger and other Aptose Biosciences executives is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. Aptose Biosciences can also be reached via phone at 858-926-2730 and via email at [email protected]. Learn More on Denis R. Burger's contact information.
Has Denis R. Burger been buying or selling shares of Aptose Biosciences?: Denis R. Burger has not been actively trading shares of Aptose Biosciences within the last three months. Most recently, on Monday, December 20th, Denis R. Burger bought 666 shares of Aptose Biosciences stock. The stock was acquired at an average cost of $21.75 per share, with a total value of $14,485.50. Learn More on Denis R. Burger's trading history.
Who are Aptose Biosciences' active insiders?: Aptose Biosciences' insider roster includes Rafael Bejar (VP), Denis Burger (Director), Erich Platzer (Director), William Rice (CEO), Warren Whitehead (Director), and Donald Wilson, Jr. (Major Shareholder). Learn More on Aptose Biosciences' active insiders.
Are insiders buying or selling shares of Aptose Biosciences?: In the last twelve months, Aptose Biosciences insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $20,000.00. The most recent insider tranaction occured on November, 25th when CEO William G Rice bought 100,000 shares worth more than $20,000.00. Insiders at Aptose Biosciences own 3.9% of the company. Learn More about insider trades at Aptose Biosciences.
Information on this page was last updated on 11/25/2024.

Denis R. Burger Insider Trading History at Aptose Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/20/2021	Buy	666	$21.75	$14,485.50

Denis R. Burger Buying and Selling Activity at Aptose Biosciences

Aptose Biosciences Company Overview

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Today's Range

Now: $0.28

$0.21

$0.39

50 Day Range

MA: $0.30

$0.17

$0.40

2 Week Range

Now: $0.28

$0.13

$2.68

Volume

304,802,594 shs

Average Volume

1,745,122 shs

Market Capitalization

$16.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06

I was wrong. Dead wrong.

From Porter & Company | Ad